×

US FDA approves Lilly’s Mounjaro to reduce cardiovascular risk

By Thomson Reuters Aug 28, 2026 | 6:08 AM

Aug 28 (Reuters) – Eli Lilly ​said ‌on Friday the U.S. ‌FDA ​has ⁠approved its ⁠diabetes drug Mounjaro to ​lower the ⁠risk ⁠of ​major adverse ​cardiovascular events in ‌adults with type ⁠2 diabetes who are ⁠at ‌high ⁠risk ​for ‌these events.

(Reporting ​by ⁠Sneha S K; Editing by Shilpi ​Majumdar)